Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.
Description
Keywords
Animals, Models, Animal, Multiple Sclerosis, Myelin Sheath, Oligodendroglia, Regenerative Medicine, Remyelination
Journal Title
Cell Stem Cell
Conference Name
Journal ISSN
1934-5909
1875-9777
1875-9777
Volume Title
26
Publisher
Elsevier BV
Publisher DOI
Sponsorship
MULTIPLE SCLEROSIS SOCIETY (50)
Wellcome Trust (203151/Z/16/Z)
European Research Council (771411)
Medical Research Council (MC_PC_12009)
Medical Research Council (G0701476)
Medical Research Council (MC_PC_17230)
Wellcome Trust (203151/Z/16/Z)
European Research Council (771411)
Medical Research Council (MC_PC_12009)
Medical Research Council (G0701476)
Medical Research Council (MC_PC_17230)
The authors acknowledge the following support: The UK Multiple Sclerosis Society (RTK, CZ, RJMF), The Adelson Medical Research Foundation (DSR, DEB, RJMF), Intramural Research Program of NINDS/NIH (DSR), European Research Council (ERC) under the European Union Horizon 2020 Re- search and Innovation Program (RTK), The Lister Institute (RTK), and a core support grant from the Wellcome and MRC to the Wellcome-Medical Research Council Cambridge Stem Cell Institute (RTK, RJMF).